| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/11/2004 | EP1126822B1 Controlled release liquid delivery compositions with low initial drug burst |
| 02/11/2004 | EP1028725B1 Use of vasopressin antagonists for treating disturbances or illnesses of the inner ear |
| 02/11/2004 | EP1003373B1 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| 02/11/2004 | EP0900007B1 Low ph acidic compositions |
| 02/11/2004 | EP0892640B1 Enteric-coated pharmaceutical compositions of mycophenolate |
| 02/11/2004 | EP0859608B1 Treating niddm with rxr agonists |
| 02/11/2004 | EP0781127B1 Anaesthetic analgesic gas mixtures containing enflurane or isoflurane in combination with sevoflurane or desflurane |
| 02/11/2004 | CN1474821A New cephalotaxanes, their method of preapartion and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapentic agents and reversal agents |
| 02/11/2004 | CN1474819A Novel imidazole derivatives, production method thereof and use thereof |
| 02/11/2004 | CN1474697A Complexes of phosphate derivatives |
| 02/11/2004 | CN1474696A Novel pharmacentical compositions with anti-diabetic activity and method for preparing same |
| 02/11/2004 | CN1474692A Treatment of premature ejaculation |
| 02/11/2004 | CN1474691A Novel uses of combined 5-HT 1A agonists and serotonin reuptake inhibitor |
| 02/11/2004 | CN1474690A Synergestic combinations comprising renin inhibitor for cardiovascular diseases |
| 02/11/2004 | CN1474688A Novel uses of combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists |
| 02/11/2004 | CN1474686A Hydrolytically unstable compositions |
| 02/11/2004 | CN1474683A Cosmetic and pharmaceutical composition and its use |
| 02/11/2004 | CN1473621A Medicinal new dosage form comtaining SA liposome as medicine carrier |
| 02/11/2004 | CN1473567A Combined therapeutic method including acrivastine and antihypertensive |
| 02/11/2004 | CN1473566A Combined therapeutic method including acrivastine and antihypertensive |
| 02/11/2004 | CN1137853C Electrolytic reduction water and its use, preparing method and device |
| 02/11/2004 | CN1137726C Method of prolonged suppression of humoral immunity |
| 02/11/2004 | CN1137722C Establishment of TONIC ovarian estrogen secretion for extended therapeutic regimens |
| 02/11/2004 | CN1137680C Aerosol compositions |
| 02/10/2004 | US6690976 Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs |
| 02/10/2004 | US6689938 Administering an antagonist of melanocortin stimulating hormone (msh) biological activity. |
| 02/10/2004 | US6689866 Isolated polypeptide comprising specified amino acid sequence; membrane-bound or secreted polypeptide having semaphorin-like activity |
| 02/10/2004 | US6689816 Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| 02/10/2004 | US6689815 Intratumoral use of dinitrochorobenzene: composition and use of injections including particular applications |
| 02/10/2004 | US6689807 Activating akt |
| 02/10/2004 | US6689787 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| 02/10/2004 | US6689783 Aryl oxime-piperazines useful as CCR5 antagonists |
| 02/10/2004 | US6689782 3-piperazinyl-2-diarylurea-quinazolinone derivatives; potentiators of antifungal agents |
| 02/10/2004 | US6689765 Viricides; antiinflammatory agents |
| 02/10/2004 | US6689756 Via catheter comprising antimicrobial agent and second catheter for withdrawing fluid; for treating infection or neoplasm of cerebrospinal tissue |
| 02/10/2004 | US6689751 Peptide comprising amino acid sequence 15 or 83 with alanine or alpha-aminoisobutyrate substitution |
| 02/10/2004 | US6689748 Method of treating mast cell activation-induced diseases with a proteoglycan |
| 02/10/2004 | US6689747 Use of insulin for the treatment of cartilagenous disorders |
| 02/10/2004 | US6689598 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 02/10/2004 | US6689597 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis |
| 02/10/2004 | US6689580 Growth factor |
| 02/10/2004 | US6689570 Antibody or antigen-binding sequences for use in the treatment of inflammatory bowel disease |
| 02/10/2004 | US6689393 Glucose concentration can be varied without influencing the concentration of the other components; three individual solutions are combined and administered after heat sterilization; calcium ions, electrolyte salts, and a buffer |
| 02/10/2004 | US6689385 Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| 02/10/2004 | US6689381 Liposome comprising phosphatidylcholine, cholesterol, as well as benzoquinazoline thymidylate synthase inhibitor; improved pharmacokinetics and efficacy as anti-tumor agents compared to free drug |
| 02/10/2004 | US6689379 Transdermal therapeutic system with neutralized acrylic adhesive patch |
| 02/10/2004 | US6689362 Method for treating T-lineage leukemias and lymphomas using a CD7-specific monoclonal antibody (TXU-7) linked to the pokeweed antiviral protein (PAP) |
| 02/10/2004 | US6689355 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 02/10/2004 | CA2359812C Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| 02/10/2004 | CA2229597C Oral fast-dissolving compositions for dopamine agonists |
| 02/10/2004 | CA2114936C Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones |
| 02/10/2004 | CA2106474C Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 02/09/2004 | CA2421269A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/06/2004 | CA2436890A1 Pharmaceutical preparation with rna as hemostasis cofactor |
| 02/05/2004 | WO2004011650A2 Antigens encoded by alternative reading frame from pathogenic viruses |
| 02/05/2004 | WO2004011640A1 Three-dimensional structure of dipeptidyl peptidase iv |
| 02/05/2004 | WO2004011637A2 Modified adamts4 molecules and method of use thereof |
| 02/05/2004 | WO2004011069A1 Medicament dispenser |
| 02/05/2004 | WO2004011068A1 Medicament dispenser |
| 02/05/2004 | WO2004011067A1 Medicament dispenser |
| 02/05/2004 | WO2004011031A1 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 02/05/2004 | WO2004011029A2 Pharmaceutical compositions for penis enlargement |
| 02/05/2004 | WO2004011017A1 Nasal irrigation solutions and methods of using same |
| 02/05/2004 | WO2004011013A1 Psoriasis formulation and method of preparation |
| 02/05/2004 | WO2004011011A1 Oral and dental composition |
| 02/05/2004 | WO2004011010A1 Myocardial perfusion imaging using a2a receptor agonists |
| 02/05/2004 | WO2004011006A1 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 02/05/2004 | WO2004010993A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 02/05/2004 | WO2004010992A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | WO2004010990A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 02/05/2004 | WO2004010987A2 Use of s1p receptor agonists in heart diseases |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010953A2 Implantable artificial organ devices |
| 02/05/2004 | WO2004010946A2 Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
| 02/05/2004 | WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | WO2004010941A2 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 02/05/2004 | WO2004010937A2 Method of treating cancer |
| 02/05/2004 | WO2004010936A2 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | WO2004010932A2 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| 02/05/2004 | WO2004010924A2 Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof |
| 02/05/2004 | WO2004010894A2 Ophthalmologic irrigation solutions and method |
| 02/05/2004 | WO2003101482A3 Liposome vaccine formulations for fin-fish |
| 02/05/2004 | WO2003097871A3 Marker molecules associated with lung tumors |
| 02/05/2004 | WO2003092589A3 Salt solution for colon cleansing |
| 02/05/2004 | WO2003089001A8 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus |
| 02/05/2004 | WO2003087818A3 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 02/05/2004 | WO2003087049A3 Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent |
| 02/05/2004 | WO2003086461A3 Use of substances for treating tumors |
| 02/05/2004 | WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 02/05/2004 | WO2003082255A3 Use of mob-5 in pain |
| 02/05/2004 | WO2003072735A3 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels |
| 02/05/2004 | WO2003070167A3 Therapeutic and prophylactic treatment of aging and disorders of aging in humans |
| 02/05/2004 | WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 02/05/2004 | WO2003066067A3 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 02/05/2004 | WO2003064455A3 Macrocyclic peptides active against the hepatitis c virus |
| 02/05/2004 | WO2003024386A3 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 02/05/2004 | WO2003020947A3 Mid 9002, a human sulfatase family member and uses therefor |
| 02/05/2004 | WO2002072776A3 Cell culture system for synthesis of infectious hepatitis c virus |